The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Respinova to market their device that clears secretions for patients with respiratory issues by facilitating the opening of airways. The device, called Pulsehaler, is the first to use patented techology known as Dynamic Multi-frequency Pressure Pulse™. Professor Raphael Breuer, MD, former Head of the Institute of Pulmonology at Hadassah University Medical Center commented on the innovation, “Despite the available pharma treatments, patients with COPD, Asthma, CF and other respiratory diseases unfortunately still suffer from poor quality of life. Pulsehaler™ brings a novel approach that will help patients with these conditions open their airways, which should improve their symptoms significantly.”

Read more here.

More on: